Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Runda Medical Technology Co (SHSE:603108) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Shanghai Runda Medical Technology Co EBITDA Margin % Related Terms
Shanghai Runda Medical Technology Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Runda Medical Technology Co EBITDA Margin % Chart
SHSE:603108 vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Shanghai Runda Medical Technology Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Runda Medical Technology Co EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Shanghai Runda Medical Technology Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Shanghai Runda Medical Technology Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Runda Medical Technology Co (SHSE:603108) has a EBITDA Margin % of 1.65% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shanghai Runda Medical Technology Co and its competitors. This is 89% below median its historical median of 15.26. According to the industry distribution chart, Shanghai Runda Medical Technology Co ranks #120 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 59.1%.
Is Shanghai Runda Medical Technology Co's EBITDA Margin % too high?
Shanghai Runda Medical Technology Co's current EBITDA Margin % of 1.65% is 89% below median its 10-year median of 15.26. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.43. Shanghai Runda Medical Technology Co's value of 1.65% is 69.6% below this industry median. Based on the distribution chart, Shanghai Runda Medical Technology Co ranks #120 out of 203 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Shanghai Runda Medical Technology Co has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Shanghai Runda Medical Technology Co's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Shanghai Runda Medical Technology Co ranks #120 out of 203 companies for EBITDA Margin %. This places Shanghai Runda Medical Technology Co in the lower half of its industry. The industry median EBITDA Margin % is 5.43. Shanghai Runda Medical Technology Co's value of 1.65% is 69.6% below this benchmark. While the company's 10-year median is 15.26 vs. the industry median of 5.43, Shanghai Runda Medical Technology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.43, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Runda Medical Technology Co's current EBITDA Margin % of 1.65% is 69.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shanghai Runda Medical Technology Co and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Runda Medical Technology Co's current EBITDA Margin % is 1.65%, which is 89% below median its own 10-year median of 15.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Runda Medical Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Runda Medical Technology Co (SHSE:603108) is currently considered Possible Value Trap. The stock's GF Value™ is ¥17.89, compared to a current price of ¥10.01 — trading 44% below its estimated fair value. The current EBITDA Margin % is 1.65%, which is 89% below median its 10-year median of 15.26 and 69.6% below the Medical Diagnostics & Research industry median of 5.43. Shanghai Runda Medical Technology Co's overall GF Score™ is 39/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Shanghai Runda Medical Technology Co (SHSE:603108), the current EBITDA Margin % is 1.65% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Runda Medical Technology Co (SHSE:603108) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Runda Medical Technology Co stock appears to be undervalued.
The current stock price of ¥10.01 is trading 44% below its estimated GF Value™ of ¥17.89.
GuruFocus considers Shanghai Runda Medical Technology Co to be Possible Value Trap.
Key valuation signals for SHSE:603108:
EBITDA Margin %: 1.65% (89% below median its 10-year median of 15.26)
GF Value™: ¥17.89 vs. price of ¥10.01 (44% below fair value)
Industry Position: 69.6% below the Medical Diagnostics & Research median (#120 of 203)
No single metric tells the full story. See the SHSE:603108 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Runda Medical Technology Co Ltd is a medical laboratory integrated service provider based in East China. The company provides in-vitro diagnostic products and professional technical support to various medical laboratories.
39GF Score
Get the complete analysis for SHSE:603108
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603108 has been successfully added to your 
